Core Viewpoint - The report highlights a positive performance in the pharmaceutical sector, particularly in the innovative drug industry, driven by ongoing licensing agreements and supportive domestic policies [3]. Fund Performance - The fund reported a profit of 26.97 million yuan in Q2 2025, with a weighted average profit per fund share of 0.0627 yuan [2]. - The fund's net asset value (NAV) growth rate for Q2 was 7.62%, and the fund size reached 375 million yuan by the end of Q2 [2][16]. - As of July 18, the fund's unit NAV was 0.96 yuan [2]. - The fund's performance over the past three months showed a NAV growth rate of 14.74%, ranking 112 out of 138 comparable funds [4]. - Over the past six months, the fund's NAV growth rate was 25.40%, ranking 100 out of 138 [4]. - The one-year NAV growth rate was 24.99%, also ranking 100 out of 133 [4]. - The three-year NAV growth rate was 4.99%, ranking 46 out of 107 [4]. Investment Strategy - The fund manager expressed optimism about the innovative drug sector, indicating a shift from a general revaluation phase to a stage where actual performance and partnerships will be tested [3]. - The strategy includes a "barbell" approach, focusing on high-probability or high-return innovative drug companies [3]. - The fund is also looking at sectors with strong performance, such as orthopedics and upstream innovative drugs, while making early allocations in improving sectors like medical devices [3]. - New technologies like AI and brain-computer interfaces are expected to transform the healthcare system, although short-term financial impacts on related companies may be limited [3]. Risk and Return Metrics - The fund's three-year Sharpe ratio was 0.1406, ranking 41 out of 105 comparable funds [9]. - The maximum drawdown over the past three years was 29.8%, ranking 97 out of 106 [11]. - The fund's average stock position over the past three years was 85.43%, slightly below the comparable average of 86.95% [14].

AI基金博时健康生活混合A（012086）披露2025年二季报，第二季度基金利润987.73万元，加权平均基金份额本期利润0.0429元。报告期内，基金净值增长 率为7.41%，截至二季度末，基金规模为1.4亿元。 截至7月18日，博时健康生活混合A近三个月复权单位净值增长率为15.09%，位于同类可比基金111/138；近半年复权单位净值增长率为25.43%，位于同类可 比基金99/138；近一年复权单位净值增长率为25.95%，位于同类可比基金97/133；近三年复权单位净值增长率为-12.42%，位于同类可比基金74/107。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比较情况。图为坐标原点到区间内某时点的净值增长率在同类基金中的分位数。 该基金属于偏股混合型基金，长期投资于医药医疗股票。截至7月18日，单位净值为0.67元。基金经理是陈西铭，目前管理3只基金近一年均为正收益。其 中，截至7月18日，博时健康生活混合A近一年复权单位净值增长率最高，达25.95%；博时医疗保健混合A最低，为11.62%。 基金管理人在二季报中表示，我们仍然看好创新药板块行情，认为行情已从所有创新药公 ...